Positron emission tomography and cancer

Oncology: An Evidence-Based Approach

Volumn , Issue , 2006, Pages 449-483

  Chatzifotiadis, Daniel N ^a   Buchanan, Julia W ^b   Wahl, Richard L ^b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77955450002     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/0-387-31056-8_33     Document Type: Chapter

References (383)

1. Wahl RL, Buchanan JW (eds). In: Principles and Practice of Positron Emission Tomography. Philadelphia: Lippincott Williams & Wilkins, 2002.
2. Laubenbacher C, Saumweber D, Wagner MC, et al. Comparison of fluorine-18-fluorodeoxyglucose PET, MRI and laryngoscopy for staging head and neck squamous cell carcinomas. J Nucl Med 2995;36:1747-1757.
3. Wong WL, Chevretton EB, McGurk M, et al. A prospective study of PET-FDG imaging for the assessment of head and neck squamous cell carcinoma. Clin Otolaryngol Appl Sci 1997;22:209-214.
4. Braams JW, Pruim J, Kole AC, et al. Detection of unknown primary head and neck tumors by positron emission tomography. Int J Oral Maxillofac Surg 1997;26:112-115.
5. Safa AA, Tran LM, Rege S, et al. The role of positron emission tomography in occult primary head and neck cancers. Cancer J Sci Am 1999;5:214-218.
6. Jungehulsing M, Scheidhauer K, Damm M, et al. 2 [F]-Fluoro-2-deoxy-d- glucose positron emission tomography is a sensitive tool for the detection of occult primary cancer (carcinoma of unknown primary syndrome) with head and neck lymph node manifestation. Otolaryngol Head Neck Surg 2000;123:294-301.
7. Greven KM, Keyes JJ, Williams DR, et al. Occult primary tumors of the head and neck: lack of benefit from positron emission tomography imaging with 2-[F-18]fluoro-2-deoxy-d-glucose. Cancer (Phila) 1999;86:114-118.
8. Rege S, Safa AA, Chaiken L, et al. Positron emission tomography: an independent indicator of radiocurability in head and neck carcinomas. Am J Clin Oncol 2000;23:164-169.
9. Adams S, Baum RP, Stuckensen T, Bitter K, Hor G. Prospective comparison of F-18-FDG-PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med 1998;25:1255-1260.
10. Kau RJ, Alexiou C, Laubenbacher C, Werner M, Schwaiger M, Arnold W. Lymph node detection of head and neck squamous cell carcinomas by positron emission tomography with fluorodeoxyglucose F-18 in a routine clinical setting. Arch Otolaryngol Head Neck Surg 1999;125:1322-1328.
11. Stokkel MP, ten Broek FW, Hordjk GJ, et al. Preoperative evaluation of patients with primary head and neck cancer using dual-head 18-fluorodeoxyglucose positron emission tomography. Ann Surg 2000;231:229-234.
12. Hannah A, Scott AM, Tochon-Danguy H, et al. Evaluation of 18 F-fluorodeoxyglucose position emission tomography and computed tomography with histopathologic correlation in the initial staging of head and neck cancer. Ann Surg 2002;236:208-217.
13. Di Martino E, Nowak B, Hassan HA, et al. Diagnosis and staging of head and neck cancer: a comparison of modern imaging modalities (positron emission tomography, computed tomography, color-coded duplex sonography) with penendoscopic and histopathologic findings. Arch Otolaryngol Head Neck Surg 2000;126:1457-1461.
14. Stuckensen T, Kovacs AF, Adams S, et al. Staging of the neck in patients with oral cavity squamous cell carcinomas: a prospective comparison of PET, ultrasound, CT and MRI. J Craniomaxillofac Surg 2000;28:319-324.
15. Schwartz LH, Ozsahin M, Zhang GN, et al. Synchronous and metachronous head and neck carcinomas. Cancer (Phila) 1994;74:1933-1938.
16. Stokkel MP, Moons KG, ten Broek FW, et al. 18 F-Fluorodeoxyglucose dual-head positron emission tomography as a procedure for detecting simultaneous primary tumors in cases of head and neck cancer. Cancer (Phila) 1999;86:2370-2377.
17. Lowe VJ, Stack BC Jr. Esophageal cancer and head and neck cancer. Semin Roentgenol 2002;37(2):140-150.
18. Goodwin WJ Jr. Salvage surgery for patients with recurrent squamous cell carcinoma of the upper aerodigestive tract: when do the ends justify the means? Laryngoscope 2000;110:1-18.
19. Goerres GW, Schmid DT, Bandhauer F, et al. Positron emission tomography in the early follow-up of advanced head and neck cancer. Arch Otolaryngol Head Neck Surg 2004;130:105-109.
20. Wax MK, Myers LL, Gona JM, Husain SS, Nabi HA. The role of positron emission tomography in the evaluation of the Npositive neck. Otolaryngol Head Neck Surg 2003;129:163-167.
21. Lapela M, Eigtved A, Jyrkkio S, et al. Experience in qualitative and quantitative FDG-PET in follow-up of patients with suspected recurrence from head and neck cancer. Eur J Cancer 2000;36:858-867.
22. Li P, Zhuang H, Mozley PD, et al. Evaluation of recurrent squamous cell carcinoma of the head and neck with FDG positron emission tomography. Clin Nucl Med 2001;26:131-135.
23. Terhaard CH, Bongers V, van Rijk PP, et al. F-18-fluorodeoxy-glucose positron-emission tomography scanning in detection of local recurrence after radiotherapy for laryngeal/pharyngeal cancer. Head Neck 2001;23:933-941.
24. Lowe VJ, Boyd JH, Dunphy FR, et al. Surveillance for recurrent head and neck cancer using positron emission tomography. J Clin Oncol 2000;18:651-658.
25. Kunkel M, Forster GJ, Reichert TE, et al. Detection of recurrent oral squamous cell carcinoma by [ 18 F]-2-fluorodeoxyglucosepositron emission tomography. Implications for prognosis and patient management radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study. Cancer (Phila) 2003;98:2257-2265.
26. Brun E, Kjellen E, Tennval J, et al. FDG-PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck 2002;24:127-135.
27. Kitagawa Y, Sadato N, Azuma H, et al. FDG-PET to evaluate combined intra-arterial chemotherapy and radiotherapy of head and neck neoplasms. J Nucl Med 1999;40:1132-1137.
28. Kitagawa Y, Nishizawa S, Sano K, et al. Prospective comparison of F-18-FDG-PET with conventional imaging modalities (MRI, CT, and Ga-67 scintigraphy) in assessment of combined intraarterial chemotherapy and radiotherapy for head and neck carcinoma. J Nucl Med 2003;44:198-206.
29. Goerres GW, Schmid DT, Bandhauer F, et al. Positron emission tomography in the early follow-up of advanced head and neck cancer. Arch Otolaryngol Head Neck Surg 2004;130:105-109; discussion 120-121.
30. Kubota K, Yokoyama J, Yamaguchi K, et al. FDG-PET delayed imaging for the detection of head and neck cancer recurrence after radio-chemotherapy: comparison with MRI/CT. Eur J Nucl Med Mol Imaging 2004;31:590-595.
31. Greven KM, Williams DW III, McGuirt WF Sr, et al. Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer. Head Neck 2001;23: 942-946.
32. Lowe VJ, Heber ME, Anscher MS, et al. Chest wall FDG accumulation in serial FDG-PET images in patients being treated for bronchogenic carcinoma with radiation. Clin Positron Imaging 1998;1:185-191.
33. Leskinen-Kallio S, Nagren K, Lehikoinen P, Ruotsalainen U, Teras M, Joensuu H. Carbon-11-methionine and PET is an effective method to image head and neck cancer. J Nucl Med 1992; 33:691-695.
34. Braams JW, Pruim J, Nikkels PGJ, Roodenburg JLN, Vaalburg W, Vermey A. Nodal spread of squamous cell carcinoma of the oral cavity detected with PET-tyrosine, MRI and CT. J Nucl Med 1996;37:897-901.
35. Nonomiya H, Oriuchi N, Kahn N, et al. Diagnosis of tumor in the nasal cavity and paranasal sinuses with [11]choline PET; comparative study with 2-F-18 fluoro-2-deoxy-d-glycose (FDG) PET. Ann Nucl Med 2004;18:29-34.
36. Cobben DCP, van der Laan B, Maas B, et al. F-18-FLT PET for visualization of laryngeal cancer: comparison with F-18-FDGPET. J Nucl Med 2004;45:226-231.
37. Lewis JS, Herrero P, Sharp TL, et al. Delineation of hypoxia in canine myocardium using PET and copper (II)-diacetyl-bis(N(4)-methylthiosemicarbazone). J Nucl Med 2002;43:1557-1569.
38. Maurer RI, Blower PJ, Dilworth JR, Reynolds CA, Zheng Y, Mullen GE. Studies on the mechanism of hypoxic selectivity in copper bis (thiosemicarbazone) radiopharmaceuticals. J Med Chem 2002;45:1420-1431.
39. Nunn A, Linder K, Strauss HW. Nitroimidazoles and imaging hypoxia. Eur J Nucl Med 1995;22:265-280.
40. Piert M, Machulla HJ, Becker G, Aldinger P, Winter E, Bares R. Dependency of the [F-18]fluoromisonidazole uptake on oxygen delivery and tissue oxygenation in the porcine liver. Nucl Med Biol 2000;27:693-700.
41. Adler LP, Bloom AD. Positron emission tomography of thyroid masses. Thyroid 1993;3:195-200.
42. Bloom AD, Adler LP, Shuck JM. Determination of malignancy of thyroid nodules with positron emission tomography. Surgery (St. Louis) 1993;114:728-734.
43. Kresnik E, Gallowitsch HJ, Mikosch P, et al. Fluorine-18- fluorodeoxyglycose positron emission tomography in the preop- erative assessment of thyroid nodules in an endemic goiter area. Surgery (St. Louis) 2003;133:294-299.
44. Borner AR, Voth E, Wienhard K, Wagner R, Schicha H. F-18-FDG-PET in autonomous goiter. Nuklear-medizin 1999;38:1-6.
45. Gianoukakis AG, Karam M, Cheema A, Cooper JA. Autonomous thyroid nodules visualized by positron emission tomography with F-18-fluorodeoxyglucose: a case report and review of the literature. Thyroid 2003;13:395-399.
46. Yasuda S, Shohtsu A, Ide M, Takagi S, Suzuki Y, Tajima T. Diffuse F-18 FDG uptake in chronic thyroiditis. Clin Nucl Med 1997;22:341.
47. Schmid DT, Kneifel S, Stoeckli SJ, Padberg BC, Merrill G, Goerres GS. Increased 18F-FDG uptake mimicking thyroid cancer in a patient with Hashimoto's thyroiditis. Eur Radiol 2003;13:2119-2121.
48. Kang KW, Kim SK, Kang HS, et al. Prevalence and risk of cancer of focal thyroid incidentaloma identified by F-18-fluorodeoxyglucose positron emission tomography for metastasis evaluation and cancer screening in healthy subjects. J Clin Endocrinol Metab 2003;88:4100-4104.
49. Cohen MS, Arslan N, Dehdashti F, et al. Risk of malignancy in thyroid incidentalomas identified by fluorodeoxyglucosepositron emission tomography. Surgery (St. Louis) 2001;130: 941-946.
50. Grunwald F, Kalicke T, Feine U, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 1999;26:1547-1552.
51. Feine U, Lietzenmayer R, Hanke JP, Held J, Whorle H, MullerSchauenburg W. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 1996;37:1468-1472.
52. Wang WP, Macapinlac H, Larson SM, et al. F-18-2-fluoro-2-deoxy-d-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic I-131 whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 1999;84:2291-2302.
53. Altenvoerde G, Lerch H, Kuwert T, Matheja P, Schafers M, Schober O. Positron emission tomography with F-18-deoxyglucose in patients with differentiated thyroid carcinoma, elevated thyroglobulin levels, and negative iodine scans. Langenbecks Arch Surg 1998;383:160-163.
54. Grunwald F, Menzel C, Bender H, et al. Comparison of 18FDGPET with 131 iodine and 99mTc-sestamibi scintigraphy in differentiated thyroid cancer. Thyroid 1997;7:327-335.
55. Maxon HR. Detection of residual and recurrent thyroid cancer by radionuclide imaging. Thyroid 1999;9:443-446.
56. Schonberger J, Ruschoff J, Grimm D, et al. Glucose transporter I gene expression is related to thyroid neoplasms with an unfavorable prognosis: an immunohistochemical study. Thyroid 2002;12:747-754.
57. Chin BB, Patel P, Cohade C, Ewertz M, Wahl R, Ladenson P. Recombinant human thyrotropin stimulation of fluorod-glucose positron emission tomography uptake in welldifferentiated thyroid carcinoma. J Clin Endocrinol Metab 2004;89:91-95.
58. Moog F, Linke R, Manthey N, et al. Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma. J Nucl Med 2000;41:1989-1995.
59. Helal BO, Merlet P, Toubert ME, et al. Clinical impact of (18)F-FDG-PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131) I scanning results after therapy. J Nucl Med 2001;42:1464-1469.
60. Schluter B, Bohuslavizki KH, Beyer W, et al. Impact of FDG-PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131 I scan. J Nucl Med 2001;42:71-76.
61. Moog F, Linke R, Manthey N, et al. Influence of thyroidstimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma. J Nucl Med 2000;41:1989-1995.
62. Petrich T, Borner AR, Otto D, et al. Influence of rhTSH on [(18)F]fluorodeoxyglucose uptake by differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging 2002;29:641-647.
63. Deichen JT, Schmidt C, Prante O, Maschauer S, Papadopoulos T, Kuwert T. Influence of TSH on uptake of F-18 fluorodeoxyglucose in human thyroid cells in vitro. Eur J Nucl Med Mol Imaging 2004;31:507-512.
64. Wang WP, Larson SM, Fazzari M, et al. Prognostic value of [F-18] fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab 2000;85:1107-1113.
65. Wang WP, Larson SM, Tuttle RM, et al. Resistance of F-18- fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. Thyroid 2001; 11:1169-1175.
66. Lowe VJ, Mullan BP, Hay ID, Mclver B, Kasperbauer JL. F-18-FDG-PET of patients with Hurthle cell carcinoma. J Nucl Med 2003;44:1402-1406.
67. Plotkin M, Hautzel H, Krause BJ, et al. Implication of 2-(18)fluoro-2-deoxyglucose positron emission tomography in the follow-up of Hurthle cell thyroid cancer. Thyroid 2002; 12:155-161.
68. Brandt-Mainz K, Muller SP, Gorges R, Saller B, Bocksch A. The value of fluorine-18 fluorodeoxy-glucose PET in patients with medullary thyroid cancer. Eur J Nucl Med 2000;27:490-496.
69. Diehl M, Risse JH, Brandt-Mainz K, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer. Results of a multicentre study. Eur J Nucl Med 2001;28:1671-1676.
70. Hoegerle S, Altehoefer C, Ghanem N, Brink I, Moser E, Nitzsche E. F-18-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med 2001;28:64-71.
71. Courgiotis L, Sarlis NJ, Reynolds JC, et al. Localization of medullary thyroid carcinoma metastasis in a multiple endocrine neoplasia type 2A patient by 6-[ 18 F]-fluorodopamine positron emission tomography. J Clin Endocrinol Metab 2003;88: 637-641.
72. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003;349:2241-2252.
73. Flamen P, Lerut A, Van Cutsem E, et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol 2000;18:3202-3210.
74. Kim K, Park SJ, Kim BT, et al. Evaluation of lymph node metastases in squamous cell carcinoma of the esophagus with positron emission tomography. Ann Thorac Surg 2001;71:290-294.
75. Fukunaga T, Okazumi S, Koide Y, et al. Evaluation of esophageal cancers using fluorine-18-fluorodeoxyglucose PET. J Nucl Med 1998;39:102-107.
76. Flanagan FL, Dehdashti F, Siegel BA, et al. Staging of esophageal cancer with FDG-PET. AJR 1997;168:417-424.
77. Mc Ateer D, Wallis F, Couper G, et al. Evaluation of 18F-FDG positron emission tomography in gastric and esophageal carcinoma. Br J Radiol 1999;72:525-529.
78. Yeung HWD, Macapinlac HA, Mazumdar M, et al. FDG-PET in esophageal cancer: incremental value over computed tomography. Clin Positron Imaging 1999;5:255-260.
79. Himeno S, Yasuda S, Shimada H, et al. Evaluation of esophageal cancer by positron emission tomography. Jpn J Clin Oncol 2002;32:340-346.
80. Kato H, Kuwano H, Nakijima M, Miyareki T. Comparison between positron emission tomography in the use of the assessment of esophageal carcinoma. Cancer 2002;94(4):921-928.
81. Yoon YC, Lee KS, Shim YM, Kim BT, Kim K, Kim TS. Metastasis to regional lymph nodes in patients with esophageal squamous cell carcinoma: CT versus FDG PET for presurgical detection prospective study. Radiology 2003;227:764-770.
82. Lerut T, Coosemans W, Decker G, et al. Cancer of the esophagus and gastro-esophageal junction: potentially curative therapies. Surg Oncol 2001;10:113-122.
83. Dehdashti F, Siegel BA. Neoplasms of the esophagus and stomach. Semin Nuclear Med 2004;34(3):198-208.
84. Lerut T, Flamen P, Ectors N, et al. Histopathologic validation of lymph node staging with FDG-PET scan in cancer of esophagus and gastroesophageal junction: a prospective study based on primary surgery with extensive lymphadenectomy. Ann Surg 2000;232:743-752.
85. Giovagnoni A, Valeri G, Ferrara C. MRI of esophageal cancer. Abdom Imaging 2002;27:361-366.
86. Motohara T, Semelka RC. MRI in staging of gastric cancer. Abdom Imaging 2002;27:376-383.
87. Kinkel K, Lu Y, Both M, et al. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology 2002;224:748-756.
88. Luketich JD, Schauer P, Meltzer CC, et al. The role of positron emission tomography in staging esophageal cancer. Am Thorac Surg 1997;64:765-769.
89. Luketich JD, Friedman DM, Weigel TL, et al. Evaluation of distant metastases in esophageal cancer: 100 consecutive positron emission tomography scans. Ann Thorac Surg 1999;68: 1133-1137.
90. Wallace MB, Nietert RJ, Earle C, et al. An analysis of multiple staging management strategies for carcinoma of the esophagus: computed tomography, endoscopic ultrasound, positron emission tomography, and thoracoscopy/ laparoscopy. Ann Thorac Surg 2002;74:1026-1032.
91. Wren SM, Stijns P, Srinivas S. Positron emission tomography in the initial staging of esophageal cancer. Arch Surg 2002;137: 1001-1006.
92. Hustinx R, Dolin RJ, Benard F, et al. Impact of attenuation correction on the accuracy of FDG-PET in patients with abdominal tumors: a free-response ROC analysis. Eur J Nucl Med 2000;27:1365-1371.
93. Wu LF, Wang BZ, Feng JL, et al. Preoperative TN staging of esophageal cancer: comparison of miniprobe ultrasonography, spiral CT and MRI. World J Gastroenterol 2003;9:219-224.
94. MRC, Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomized controlled trial. Lancet 2002;359:1727-1733.
95. Beseth BD, Bedford R, Isacoff WH, et al. Endoscopic ultrasound does not accurately assess pathologic stage of esophageal cancer after neoadjuvant chemoradiotherapy. Am Surg 2000;66: 827-831.
96. Laterza E, de Manzoni G, Guglielmi A, et al. Endoscopic ultrasonography in the staging of esophageal carcinoma after preoperative radiotherapy and chemotherapy. Ann Thorac Surg 1999;67:1466-1469.
97. Weber WA, Ott K, Becker K, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of esophagogastric junction by metabolic imaging. J Clin Oncol 2001;19:3058-3065.
98. Weber WA, Ott K. Imaging of esophageal and gastric cancer. Semin Oncol 2004;31(4):530-541.
99. Brucher BL, Weber W, Bauer M, et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg 2001;233:300-309.
100. Flamen P, Van Cutsem E, Lerut A, et al. Positron emission tomography for assessment of the response to induction chemotherapy in locally advanced esophageal cancer. Ann Oncol 2002;13:361-368.
101. Downey RJ, Akhurst T, Ilson D, et al. Whole body 18 FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol 2003;21:428-432.
102. Arslan N, Miller TR, Dehdashti F, Battafarano RJ, Siegel BA. Evaluation of response to neoadjuvant therapy by quantitative 2-deoxy-2-[ 18 F] fluoro-d-glucose with positron emission tomography in patients with esophageal cancer. Mol Imaging Biol 2002;4:301-310.
103. Fukunaga T, Enomoto K, Okazumi S, et al. Analysis of glucose metabolism in patients with esophageal cancer by PET: estimation of hexokinase activity in the tumor and usefulness for clinical assessment using FDG. Nippon Geka Gakka Zasshi 1994;95:317-325.
104. Yeung HW, Macapinlac HA, Mazumdar M, Bains M, Finn RD, Larson SM. FDG-PET in esophageal cancer, incremental value over computed tomography. Clin Positron Imaging 1999;2: 255-260.
105. Flamen P, Lerut A, Van Cutsem E, et al. The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer. J Thorac Cardiovasc Surg 2000;120: 1085-1092.
106. Boring CC, Squires TS, Tong T. Cancer statistics, 1992. CA Cancer J Clin 1992;42(1):19-38.
107. Stoller JK, Ahmad M, Rice W. Solitary pulmonary module. Cleve Clin J Med 1988;55(I):68-74.
108. Dewan NA, Gupta NC, Redepenning LS, et al. Diagnostic efficacy of PET-FDG imaging in solitary pulmonary modules. Potential role in evaluation and management. Chest 1993; 104(4):997-1002.
109. Erasmus JJ, Connolly JE, McAdams HP, et al. Solitary pulmonary nodules: Part I. Morphologic evaluation for differentiation of benign and malignant lesion. Radiographics 2000;20:43-58.
110. Gurney JW, Lyddon DM, McKay JA. Determining the likelihood of malignancy in solitary pulmonary nodules with Bayesian analysis. Part II. Application. Radiology 1993;186(2):415-422.
111. Winning AJ, Mclvor J, Seed WA, et al. Interpretation of negative results in fine needle aspiration of discrete pulmonary lesions. Thorax 1986;41(11):875-879.
112. Lowe VJ, Duhaylongsod FD, Patz EF, et al. Pulmonary abnormalities and PET data analysis: a retrospective study. Radiology 1997;202(2):435-439.
113. Goo JM, Im JG, Do KH, et al. Pulmonary tuberculoma evaluated by means of FDG PET: findings in 10 cases. Radiology 2000;216:117-121.
114. Lewis PJ, Salama A. Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nucl Med 1994;35:1647-1649.
115. Wilkinson MD, Fulham MJ, Mc Caughan BC, et al. Invasite aspergillosis mimicking stage IIIA non-small-cell lung cancer on FDG positron emission tomography. Clin Nucl Med 2003;28: 234-235.
116. Croft DR, Trapp J, Kernstine K, et al. FDG-PET imaging and the diagnosis of non-small cell lung cancer in a region of high hitoplasmosis prevalence. Lung Cancer 2002;36:297-301.
117. Bender H, Palmedo H, Biersack HJ, et al. Atlas of Clinical PET in Oncology: PET Versus CT and MRI. Berlin: Springer, 2000.
118. Frank A, Lefkowitz D, Jaeger J, et al. Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings. Int J Radiat Oncol Biol Phys 1995;32(5):1495-1512.
119. Yap CS, Schiepers C, Fishbein MC, et al. FDG-PET imaging in lung cancer: how sensitive is it for bronchoalveolar carcinoma? Eur J Nucl Med Mol Imaging 2002;29:1166-1173.
120. Erasmus JJ, McAdams HP, Patz EF Jr, et al. Evaluation of primary pulmonary carcinoid tumors using FDG PET. AJR Am J Roentgenol 1998;170:1369-1373.
121. Gould MK, Maclean CC, Kuschner WG, et al. Accuracy of positron emission tomography for diagnosis of pulmonary modules and mass lesions. JAMA 2001;285(7):914-924.
122. Swensen SJ, Viggiano RW, Midthun DE, et al. Lung nodule enhancement at CT: multicenter study. Radiology 2000;214: 73-80.
123. Nathan MA, Mullan BP, Hartman TE. Characterization of the solitary pulmonary module 18 F-FDG PET versus nodule enhancement CT. Eur J Nucl Med 2003;30(suppl 2):S151.
124. Rohren EM, Lowe VJ. Update in PET imaging of non-small cell lung cancer. Semin Nucl Med 2004;34(2):134-153.
125. Marom EM, Sarvis S, Herndon JE, et al. T1 lung cancers: sensitivity of diagnosis with fluorodeoxyglucose PET. Radiology 2002;223:453-459.
126. Zhuang H, Pourdehnad M, Lambright ES, et al. Dual time point 18 F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med 2001;42:1412-1417.
127. Matthies A, Hickeson M, Cuchiara A, et al. Dual time point 18 F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med 2002;43:871-875.
128. Demura Y, Tsuchida T, Ishizaki T, et al. 18 F-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax. J Nucl Med 2003;44:540-548.
129. Marom EM, McAdams HP, Erasmus JJ, et al. Staging non-small cell lung cancer with whole-body PET. Radiology 1999;212(3): 803-809.
130. Erasmus JJ, Patz EF, McAdams HP, et al. Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18 Ffluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol 1997;168(5):1357-1360.
131. Dwamena BA, Seema SS, Angobaldo JO, et al. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s. Meta-analytic comparison of PET and CT. Radiology 1999; 213(2):530-536.
132. Wahl RL, Quint LE, Greenough RL, et al. Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation. Radiology 1994; 191:371-377.
133. Steinert HC, Hauser M, Allemann F, et al. Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling. Radiology 197;202:441-446.
134. Vansteenkiste JF, Mortelmans LA. FDG-PET in the locoregional lymph node staging of non-small cell lung cancer. A comprehensive review of the Leuven lung cancer group experience. Clin Positron Imaging 1999;2:223-231.
135. Pieterman RM, van Putten JW, Meuzelaar JJ, et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 2000;343:254-261.
136. Bury T, Corhay JL, Duysinx B, et al. Value of FDG-PET in detecting residual or recurrent non-small cell lung cancer. Eur Respir J 1999;14(6):1376-1380.
137. Mah K, Cladwell CB, Ung YC, et al. The impact of ( 18 )F-FDGPET on target and critical organs in CT-based treatment planning of patients with poorly defined non-small-cell lung carcinoma: a prospective study. Int J Radiat Oncol Biol Phys 2002;52:339-350.
138. Erdi YE, Rosenzweig K, Erdi AK, et al. Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). Radiother Oncol 2002;62: 51-60.
139. Jeong HJ, Min JJ, Park JM, et al. Determination of the prognostic value of ( 18 F)fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer. Nucl Med Commun 2002;23:865-870.
140. Ahuja V, Coleman RE, Herndon J, et al. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer (Phila) 1998;83:918-924.
141. Dhital K, Saunders CA, Seed PT, et al. [ 18 F]Fluorodeoxyglucose positron emission tomography and its prognostic value in lung cancer. Eur J Cardiothorac Surg 2000;18:425-428.
142. Yasukawa T, Yoshikawa K, Aoyagi H, et al. Usefulness of PET with11 C-methionine for the detection of hilar and mediastinal lymph node metastasis in lung cancer. J Nucl Med 2000;41: 283-290.
143. Hustinx R, Lemaire C, Jerusalem G, et al. Whole-body tumor imaging using PET and 2-18 F-fluoro-l-tyrosine: preliminary evaluation and comparison with 18 F-FDG. J Nucl Med 2003;44:533-539.
144. Greenlee RT, Murray T, Hill-Harmon MB, et al. Cancer statistics 2001. CA Cancer J Clin 2001;51:15-35.
145. Wingo PA, Cardinez CJ, Landis SH, et al. Long-term trends in cancer mortality in the United States, 1930-1998. Cancer (Phila) 2003;97(suppl 12):3133-3175.
146. Brown RS, Wahl RL. Overexpression of Glut-1-glucose transporter in human breast cancer: an immunohistochemical study. Cancer (Phila) 1993;72:2979-2985.
147. Minn H, Soini I. [ 18 F]Fluorodeoxyglucose scintigraphy in diagnosis and follow-up of treatment in advanced breast cancer. Eur J Nucl Med 1989;15(2):61-66.
148. Wahl RL, Cody RL, Hutchins GD, Mudgett EE. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-d-glucose. Radiology 1991;179(3):765-770.
149. Kuota K, Matsuzawa T, Amemiya A, et al. Imaging of breast cancer with [ 18 F] fluorodeoxyglucose and positron emission tomography. J Comput Assist Tomogr 1989;13(6):1097-1098.
150. Avril N, Rose CA, Schelling M, et al. Breast imaging with positron emission tomography and [fluorine-18]-fluorodeoxyglucose: use and limitations. J Clin Oncol 2000;18:3495-3502.
151. Schirrmeister H, Kuhn T, Guhlmann A, et al. Fluorine-18-2-deoxy-2-fluoro- d-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Eur J Nucl Med 2001;28(3):351-358.
152. Walter C, Scheidhauer K, Scharl A, et al. Clinical and diagnostic value of preoperative MR mammography and FDG-PET in suspicious breast lesions. Eur Radiol 2003;13(7):1651-1656.
153. Heinisch M, Gallowitsch HJ, Mikosch P, et al. Comparison of FDG-PET and dynamic contrast-enhanced MRI in the evaluation of suggestive breast lesions. Breast 2003;121(1):17-22.
154. Samson D, Flamm CR, Aronson N. FDG positron emission tomography for evaluation of breast cancer. Washington, DC: Blue Shield and Blue Cross Association, 2001:1-93.
155. Adler LP, Crowe JP, al-Kaisi NK, Sunshine JL. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-d-glucose PET. Radiology 1993;187(3):743-750.
156. Dehdashti F, Mortimer JE, Siegel BA, et al. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med 1995;36(10):1766-1774.
157. Morrow M, Harris JR. Local management of invasive breast cancer. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds). Diseases of the Breast, 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 2000:515-560.
158. Weinberg I, Majewski S, Weisenberger A, et al. Preliminary results for positron emission mammography: real-time functional breast imaging in a conventional mammography gantry. Eur J Nucl Med 1996;23:804-806.
159. Murthy K, Aznar M, Thompson CJ, et al. Results of preliminary clinical trials of the positron emission mammography system PEM-I: a dedicated breast imaging system producing glucose metabolic images using FDG. J Nucl Med 2000;41:1851-1858.
160. Murthy K, Aznar M, Bergman AM, et al. Positron emission mammographic instrument: initial results. Radiology 2000; 215:280-285.
161. Crippa F, Seregni E, Agresti R, et al. Association between [ 18 F]-fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labeling index and p53 in primary breast cancera preliminary observation. Eur J Nucl Med 1998;25:1429-1434.
162. Avril N, Menzel M, Dose J, et al. Glucose metabolism of breast cancer assessed by 18 F-FDG-PET: histologic and immunohistochemical tissue analysis. J Nucl Med 2001;42:9-16.
163. Buck A, Schirrmeister H, Kuhn T, et al. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging 2002;29:1317-1323.
164. Adler LP, Crowe JP, Al-Kaisi NK, et al. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluorod-glucose PET. Radiology 1993;187:743-750.
165. Crowe JP Jr, Adler LP, Shenk RR, et al. Positron emission tomography and breast masses: comparison with clinical, mammographic, and pathological findings. Ann Surg Oncol 1994;1: 132-140.
166. Oshida M, Uno K, Suzuki M, et al. Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-[ 18 F] fluoro-d-glucose. Cancer (Phila) 1998;82: 2227-2234.
167. Bos R, van Der Hoeven JJ, van Der Wall E, et al. Biologic correlates of [ 18 F]-fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 2002;20:379-387.
168. Crippa F, Agresti R, Seregni E, et al. Prospective evaluation of [fluorine-18]-FDG-PET in presurgical staging of the axilla in breast cancer. J Nucl Med 1998;39:4-8.
169. Dehdashti F, Mortimer JE, Siegel BA, et al. Positron tomographic assessment of estrogen receptors in breast cancer: Comparison with FDG-PET and in vitro receptor assays. J Nucl Med 1995; 36:1766-1774.
170. Eubank WB, Mankoff DA. Current and future uses of positron emission tomography in breast cancer imaging. Semin Nucl Med 2004;34(3):224-240.
171. Mankoff DA, Dunnwald LK, Gralow JR, et al. Blood flow and metabolism in locally advanced breast cancer (LABC): relationship to response to therapy. J Nucl Med 2002;43:500-509.
172. Gottleib E, Heiden MV, Thompson CB. Bcl-x1 prevents the initial disease to mitochondrial membrane potential and subsequent reactive oxygen species production during tumor necrosis factor alpha-induced apoptosis. Mol Cell Biol 2000;20:5680-5689.
173. West KA, Castillo SS, Dennis PA. Activation of the P13K/Akt pathway and chemotherapeutic resistance. Drug Resist Update 2002;6:234-248.
174. Hellman S, Harris JR. Natural history of breast cancer. In: Harris JR, Lippman ME, Marrow M, Osborne CK (eds). Diseases of the Breast, 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 2000:407-423.
175. Wahl RL, Siegel BA, Coleman RE, Gatsonis CG. Prospective multicenter
176. Kumar R, Potenta S, Loving VA, et al. FDG-PET positive lymph modes are highly predictive of metastasis in breast cancer. J Nucl Med 2004;45(suppl):154 (abstract).
177. Zornoza G, Garcia-Velloso MJ, Sola J, Regueira FM, Pina L, Beorlegui C. 18 F-FDG PET complemented with sentinel lymph node biopsy in the detection of axillary involvement in breast cancer. Eur J Surg Oncol 2004;30(1):15-19.
178. Greco M, Crippa F, Agresti R, et al. Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-d-glucose-positron emission tomography: clinical evaluation and alternative management. J Natl Cancer Inst 2001;93(8):630-635.
179. Schirrmeister H, Kuhn T, Guhlmann A, et al. Fluorine-18-2-deoxy-2-fluoro- d-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Eur J Nucl Med 2001;28(3):351-358.
180. Avril N, Dose J, Janicke F, et al. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2(fluorine-18)-fluoro-2-deoxy-d-glucose. J Natl Cancer Inst 1996;88(17):1204-1209.
181. Freneaux P, Nos C, Vincent-Salomon A, et al. Histological detection of minimal metastatic involvement in axillary sentinel nodes: a rational basis for a sensitive methodology usable in daily practice. Mod Pathol 2002;15(6):641-646.
182. Yeatman TJ, Cox CE. The significance of breast cancer lymph node micrometastases. Surg Oncol Clin N Am 1999;8:481-496.
183. Wahl Rl, Kaminski MS, Either SP, et al. The potential of 2-deoxy-2-fluoro-d-glucose (FDG) for detection of tumor involvement in lymph nodes. J Nucl Med 1990;31:1831-1835.
184. Albertini JJ, Lyman GH, Cox C, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 1996;276:1818-1822.
185. Barranger E, Grahek D, Antoine M, et al. Evaluation of fluorodeoxyglucose positron emission tomography in the detection of axillary lymph node metastases in patients with early stage breast cancer. Ann Surg Oncol 2003;10:622-627.
186. Guller U, Nitzsche EU, Schirp U, et al. Selective axillary surgery in breast cancer patients based on positron emission tomography with 18 F-fluoro-2-deoxy-d-glucose: not yet! Breast Cancer Res Treat 2002;71:171-173.
187. Kelemen PR, Lowe V, Phillips N. Positron emission tomography and sentinel lymph node dissection in breast cancer. Clin Breast Cancer 2002;3:73-77.
188. Wagner JD, Schauwecker D, Davidson D, et al. Prospective study of fluorodeoxyglucose: positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy. J Clin Oncol 1999;17:1508-1515.
189. Cody HS III, Urban JA. Internal mammary node status: a major prognosticator in axillary node-negative breast cancer. Ann Surg Oncol 1995;2:32-37.
190. Katz A, Strom EA, Buchholz TA, et al. Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: Implications for postoperative irradiation. J Clin Oncol 2000;18:2817-2827.
191. Hathaway PB, Mankoff DA, Maravilla KR, et al. Value of combined FDG PET and MR imaging in the evaluation of suspected recurrent local-regional breast cancer: preliminary experience. Radiology 1999;210(3):807-814.
192. Ahmad A, Barrington S, Maisey M, Rubens RD. Use of positron emission tomography in evaluation of brachial plexopathy in breast cancer patients. Br J Cancer 1999;79(3-4):478-482.
193. Eubank WB, Mankoff DA, Takasugi J, et al. 18 Fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer. J Clin Oncol 2001;19:3516-3523.
194. Moon DH, Maddahi J, Silverman DH, Glaspy JA, Phelps ME, Hoh CK. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. J Nucl Med 1998;39(3):431-435.
195. Gallowitsch HJ, Kresnik E, Gasser J, et al. F-18 fluorodeoxyglucose positron emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging. Invest Radiol 2003;38(5):250-256.
196. Lonneux M, Borbath I, Berliere M, et al. The place of whole-body PET FDG for the diagnosis of distant recurrence of breast cancer. Clin Positron Imaging 2000;3:45-49.
197. Kamel EM, Wyss MT, Fehr MK, von Schulthess GK, Goerres GW. [18 F]-Fluorodeoxyglucose positron emission tomography in patients with suspected recurrence of breast cancer. J Cancer Res Clin Oncol 2003;129(3):147-153.
198. Inoue T, Yutani K, Taguchi T, Tamaki Y, Shiba E, Noguchi S. Preoperative evaluation of prognosis in breast cancer patients by [ 18 F]2-deoxy-2-fluoro-d- glucose-positron emission tomography. J Cancer Res Clin Oncol 2004;130(5):273-278.
199. Nielsen OS, Munro AJ, Tannock IF. Bone metastases: pathophysiology and management policy. J Clin Oncol 1991;9: 509-524.
200. Cook GJ, Houston S, Rubens R, et al. Detection of bone metastases in breast cancer by 18 FDG-PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 1998; 16:3375-3379.
201. Mundy GR, Guise TA, Yoneda T. Biology of bone metastases. In: Harris JR, Lippman ME, Marrow M, Osborne CK (eds). Diseases of the Breast, 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 2000:911-920.
202. Schirrmeister H, Guhlmann A, Kotzerke J, et al. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol 1999;17:2381-2389.
203. Yap CS, Seltzer MA, Schieppers C, et al. Impact of whole body of FDG-PET on the staging and managing patients with breast cancer: the referring physicians perspective. J Nucl Med 2001;42:1334-1337.
204. Eubank WB, Mankoff DA, Takasugi J, et al. 18-Fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer. J Clin Oncol 2001;19(15):3516-3523.
205. Wahl RL, Zasadny K, Helvie MA, et al. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 1993;11:2101-2111.
206. Schelling M, Avril N, Nahrig J, et al. Positron emission tomography using [ 18 F] fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000;18(8): 1689-1695.
207. Smith IC, Welch AE, Hutcheon AW, et al. Positron emission tomography using [ 18 F]-fluorodeoxy-d-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 2000;18(8):1676-1688.
208. Vranjesevic D, Filmont JE, Meta J, et al. Whole-body (18)F-FDG PET and conventional imaging for predicting outcome in previously treated breast cancer patients. J Nucl Med 2002; 43(3):325-329.
209. Jain RK. Haemodynamic and transport barriers to the treatment of solid tumors. Int J Radiat Biol 1991;60:85-100.
210. Mankoff DA, Dunnwald LK, Gralow JR, et al. Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. J Nucl Med 2003;44: 1806-1814.
211. Sugawara Y, Fisher SJ, Zasadny KR, et al. Preclinical and clinical studies of bone marrow uptake of fluorine-18-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy. J Clin Oncol 1998;16:173-180.
212. Abdel-Dayem HM, Rosen G. El-Zeftawy H, et al. Fluorine-18 fluorodeoxyglucose splenic uptake from extramedullary hematopoiesis after granulocyte colony-stimulating factor stimulation. Clin Nucl Med 1999;24:319-22.
213. Smith IC, Welch AE, Hutcheon AW, et al. Positron emission tomography using [ 18 F]-fluorodeoxy-d-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 2000;18:1676-1688.
214. Gennari A, Donati S, Salvadori B, et al. Role of 2-[ 18 F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastatic breast cancer patients. Clin Breast Cancer 2000;1:156-161.
215. Stafford SE, Gralow JR, Schubert EK, et al. Use of serial FDGPET to measure the response of bone-dominant breast cancer to therapy. Acad Radiol 2001;9:913-921.
216. Mortimer JE, Dehdashti F, Siegel BA, et al. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol 2001;19:2797-2803.
217. Tannock IF. Cell proliferation. In: Tannock IF, Hill RP (eds). The Basic Science of Oncology. New York: McGraw-Hill, 1992.
218. Shields AF, Mankoff DA, Link JM, et al. [Carbon-11]-thymidine and FDG to measure therapy response. J Nucl Med 1998; 39:1757-1762.
219. Shields AJ, Grierson J, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 1998;4:1334-1336.
220. Grierson JR, Shields AF. Radiosynthesis of 3-deoxy-3-[ 18 F]fluorothymidine[ 18 F]FLT for imaging of cellular proliferation in vivo. Nucl Med Biol 2000;27:143-156.
221. Vesselle H, Grierson J, Muzi M, et al. In vivo validation of 3-deoxy-3-[ 18 F]fluorothymidine[ 18 F]FLT) as a proliferation imaging tracer in humans: correlation of [ 18 F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res 2002;8:3315-3323.
222. Sutherland RM. Tumor hypoxia and gene expression- implications for malignant progression and therapy. Acta Oncol 1998;37:567-574.
223. Teicher BA. Hypoxia and drug resistance. Cancer Metastasis Rev 1994;13:139-168.
224. Rajendran JG, Mankoff DA, O'Sullivan F, et al. Hypoxia and glucose metabolism in malignant tumors: evaluation by FMISO and FDG-PET imaging. Clin Cancer Res 2004;10:2245-2252.
225. Clavo AC, Wahl RL. Effects of hypoxia on the uptake of tritiated thymidine, l-leucine, l-methionine and FDG in cultured cancer cells. J Nucl Med 1996;37:502-506.
226. Rajendran JG, Krohn KA. Imaging tumor hypoxia. In: Bailey DL, Townsend DW, Valk PE, Maisey MN (eds). Positron Emission Tomography: Principles and Practice. London: Springer Verlag, 2002:689-696.
227. Sledge GJ, McGuire W. Steroid hormone receptors in human breast cancer. Adv Cancer Res 1983;38:61-75.
228. Elledge RM, Fuqua SAW. Estrogen and progesterone. In: Harris JR, Lippman ME, Marrow M, Osborne CK (eds). Diseases of the Breast, 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 2000:471-488.
229. Ravdin PM, Green S, Dorr TM, et al. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol 1992;10:1284-1291.
230. Mintum MA, Welch MJ, Siegel BA, et al. Breast cancer: PET imaging of estrogen receptors. Radiology 1988;169:45-48.
231. Mankoff DA, Peterson LM, Petra PH, et al. Factors affecting the level and heterogeneity of uptake of [ 18 F]fluoroestradiol (FES) in patients with estrogen receptor positive (ER+) breast cancer. J Nucl Med 2002;43:287P (abstract).
232. McGuire AH, Dehdashti F, Siegel BA, et al. Positron tomographic assessment of 16alpha-[F-18]-fluoro-17beta-estradiol uptake in metastatic breast carcinoma. J Nucl Med 1991;32: 1526-1531.
233. Mankoff DA, Peterson LM, Tewson TJ, et al. [ 18 F]-Fluoroestradiol radiation dosimetry in human PET studies. J Nucl Med 2001;42:679-684.
234. Mankoff DA, Peterson LM, Tewson TJ, et al. Noninvasive PET imaging of ER expression in breast cancer: sex steroid binding protein (SBP or SHBG) interaction and ER expression heterogenicity. Proc AACR 2001;42:6 (abstract).
235. Dehdashti F, Morimer JE, Siegel BA, et al. Positron tomographic assessment of estrogen receptors in breast cancer. Comparison with FDG-PET and in vitro receptor assays. J Nucl Med 1995;36:1766-1774.
236. Mortimer JE, Dehdashti F, Sieger BA, et al. Clinical correlation of FDG-PET imaging with estrogen receptor and response to systemic therapy. Clin Cancer Res 1996;2:933-939.
237. Mortimer JE, Dehdashti F, Siegel BA, et al. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol 2001;19:2797-2803.
238. Vogel C, Schoenfelder J, Shemano I, et al. Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer. J Clin Oncol 1995;13:1123-1128.
239. Legha S. Tamoxifen in the treatment of breast cancer. Ann Intern Med 1988;109:219-228.
240. Chan AO, Wong BC, Lam SK. Gastric cancer: past, present and future. Can J Gastroenterol 2001;15:469-474.
241. Stahl A, Ott K, Weber WA, et al. FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging 2003;30:288-295.
242. Kawamura T, Kusakabe T, Sugino T, et al. Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastases and patient survival. Cancer 2001;92:634-641.
243. De Potter T, Flamen P, Van Cutsem E, et al. Whole-body PET with FDG for the diagnosis of recurrent gastric cancer. Eur J Nucl Med Mol Imaging 2002;29:525-529.
244. Yeung HWD, Macapinlac HA, Karpeh M, et al. Accuracy of FDG-PET in gastric cancer: preliminary experience. Clin Positron Imaging 1999;4:213-221.
245. Mochiki E, Kuwano H, Katoh H, Asao T, Oriuchi N, Endo K. Evaluation of 18 F-2-deoxy-2-fluoro-d-glucose positron emission tomography for gastric cancer. World J Surg 2004;28:247-253.
246. Yoshioka T, Yamaguchi K, Kubota K, et al. Evaluation of 18F-FDG PET in patients with advanced, metastatic, or recurrent gastric cancer. J Nucl Med 2003;44:690-699.
247. Ott K, Fink U, Becker K, et al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol 2003;21:4604-4610.
248. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
249. Kievit J. Follow-up of patients with colorectal cancer: numbers needed to test and treat. Eur J Cancer 2002;38:986-999.
250. Longo WE, Johnson FE. The preoperative assessment and postoperative surveillance of patients with colon and rectal cancer. Surg Clin N Am 2002;82:1091-1108.
251. Abdel-Nabi H, Doerr RJ, Lamonica DM, et al. Staging of primary colorectal carcinomas with fluorine-18 fluoro-deoxyglucose whole-body PET: correlation with histopathologic and CT findings. Radiology 1998;206:755-760.
252. Kantorova I, Lipska L, Belohlavek O, Visokai V, Trubac M, Schneiderova M. Routine (18)F-FDG PET preoperative staging of colorectal cancer: comparison with conventional staging and its impact on treatment decision making. J Nucl Med 2003;44:1784-1788.
253. Mukai M, Sadahiro S, Yasuda S, et al. Preoperative evaluation by whole-body 18 F-fluorodeoxyglucose positron emission tomography in patients with primary colorectal cancer. Oncol Rep 2000;7:85-87.
254. Yasuda S, Fujii H, Nakahara T, et al. 18F-FDG PET detection of colonic adenomas. J Nucl Med 2001;42:989-992.
255. Hughes KS, Simon R, Songhorabodi S, et al. Resection of liver for colorectal carcinoma metastases: a multi-institutional study of indications for resection. Surgery (St. Louis) 1988; 103:278-288.
256. Moertel CG, Fleming TR, McDonald JS, et al. An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA 1993;270:943-947.
257. Chen YM, Ott DJ, Wolfman NT, et al. Recurrent colorectal carcinoma: evaluation with barium enema examination and CT. Radiology 1987;163:307-310.
258. Charnsangavej C, Whitley NO. Metastases to the pancreas and peripancreatic lymph nodes from carcinoma of the right colon: CT findings in 12 patients. AJR 1993;160:49-52.
259. McDaniel KP, Charnsangavej C, Dubrow R, et al. Pathways of nodal metastases in carcinoma of the cecum, ascending colon and transverse colon: CT demonstration. AJR 1993;161:61-64.
260. Small WC, Mehard WB, Langmo LS, et al. Preoperative determination of the resectability of hepatic tumors: efficacy of CT during arterial portography. AJR 1993;161:319-322.
261. Petrson MS, Baron RL, Dodd GD III, et al. Hepatic parenchymal perfusion detected with CTPA: imaging-pathologic correlation. Radiology 1992;183:149-155.
262. Schiepers C, Penninckx F, De Vadder N, et al. Contribution of PET in the diagnosis of recurrent colorectal cancer: comparison with conventional imaging. Eur J Surg Oncol 1995;21:517-522.
263. Huebner RH, Park KC, Shepherd JE, et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med 2000;41:1177-1189.
264. Whiteford MH, Whiteford HM, Yee LF, et al. Usefulness of FDGPET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum. Dis Colon Rectum 2000;43:759-767; discussion 767-770.
265. Berger KL, Nicholson SA, Dehdashti F, et al. FDG PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic features. Am J Roentgenol 2000;174:1005-1008.
266. Kinkel K, Lu Y, Both M, et al. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology 2002;224:748-756.
267. Delbeke D, Vitola J, Sandler MP, et al. Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med 1997;38: 1196-1201.
268. Ogunbiyi OA, Flanagan FL, Dehdashti F, et al. Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography. Ann Surg Oncol 1997;4:613-620.
269. Rydzewski B, Dehdashti F, Gordon BA, Teefey SA, Strasberg SM, Siegel BA. Usefulness of intraoperative sonography for revealing hepatic metastases from colorectal cancer in patients selected for surgery after undergoing FDG PET. AJR Am J Roentgenol 2002;178:353-358.
270. Valk PE, Abella-Columna E, Haseman MK, et al. Whole-body PET imaging with F-18-fluorodeoxyglucose in management of recurrent colorectal cancer. Arch Surg 1999;134:503-511.
271. Gambhir SS, Czernin J, Schimmer J, et al. A tabulated review of the literature. J Nucl Med 2001;42(suppl):9S-12S.
272. Flanagan FL, Dehdashti F, Ogunbiyi OA, et al. Utility of FDG PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg 1998;227:319-323.
273. Flamen P, Hoekstra OS, Homans F, et al. Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET). Eur J Cancer 2001;37:862-869.
274. Cohade C, Osman M, Leal J, et al. Direct comparison of FDG PET and PET-CT imaging in colorectal carcinoma. J Nucl Med 2003;44:1797-1803.
275. Strasberg SM, Dehdashti F, Siegel BA, et al. Survival of patients evaluated by FDG PET before hepatic resection for metastatic colorectal carcinoma: a prospective database study. Ann Surg 2001;33:320-321.
276. Ruers TJ, Langenhoff BS, Neeleman N, et al. Value of positron emission tomography with [F-18] fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study. J Clin Oncol 2002;20:388-395.
277. Imdahl A, Reinhardt MJ, Nitzsche EU, et al. Impact of 18 F-FDGpositron emission tomography for decision making in colorectal cancer recurrences. Arch Surg 2000;385:129-134.
278. Staib L, Schirrmeister H, Reske SN, et al. Is (18)Ffluorodeoxyglucose positron emission tomography in recurrent colorectal cancer a contribution to surgical decision making? Am J Surg 2000;180:1-5.
279. Kalff VV, Hicks R, Ware R. F-18 FDG PET for suspected or confirmed recurrence of colon cancer. A prospective study of impact and outcome. Clin Positron Imaging 2000;3:183.
280. Meta J, Seltzer M, Schiepers C, et al. Impact of 18 F-FDG PET on managing patients with colorectal cancer: the referring physicians perspective. J Nucl Med 2001;42:586-590.
281. Ruers TJ, Langenhoff BS, Neeleman N, et al. Value of positron emission tomography with [F-18] fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study. J Clin Oncol 2002;20:388-395.
282. Strasberg SM, Dehdashti F, Siegel BA, et al. Survival of patients evaluated by FDG PET before hepatic resection for metastatic colorectal carcinoma: a prospective database study. Ann Surg 2001;33:320-321.
283. Delbeke D, Martin WH, Patton JA, et al. Value of iterative reconstruction, attenuation correction, and image fusion in the interpretation of FDG PET images with an integrated dual-head coincidence camera and x-ray-based attenuation maps. Radiology 2001;218:163-171.
284. Martinelli M, Townsend D, Meltzer C, et al. Survey of results of whole body imaging using the PET/CT at the University of Pittsburgh Medical Center PET facility. Clin Positron Imaging 2000;3:161.
285. Yeung HW, Schoder H, Larson SM. Utility of PET/CT for assessing equivocal PET lesions in oncology: initial experience. J Nucl Med 2002;43:32P.
286. Bar-Shalom R, Yefremov N, Guralnik L, et al. Clinical performance of PET/CT in the evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med 2003;44:1200-1209.
287. Roman CD, Delbeke D. Incremental diagnostic value of fusion imaging with integrated PET-CT in oncology compared to PET alone. RSNA Scientific Program 2003:487.
288. Beets G, Penninckx F, Schiepers C, et al. Clinical value of wholebody positron emission tomography with [ 18 F] fluorodeoxyglucose in recurrent colorectal cancer. Br J Surg 1994;81:1666-1670.
289. Strauss LG, Clorius JH, Schlag P, et al. Recurrence of colorectal tumors: PET evaluation. Radiology 1989;170:329-332.
290. Moore HG, Akhurst T, Larson SM, et al. A case controlled study of 18-fluorodeoxyglucose positron emission tomography in the detection of pelvic recurrence in previously irradiated rectal cancer patients. J Am Coll Surg 2003;197:22-28.
291. Schiepers C, Haustermans K, Geboes K, Filez L, Bormans G, Penninckx F. The effect of preoperative radiation therapy on glucose utilization and cell kinetics in patients with primary rectal carcinoma. Cancer (Phila) 1999;85:803-811.
292. Guillem JG, Puig-La Calle J Jr, Akhurst T, et al. Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography. Dis Colon Rectum 2000;43:18-24.
293. Calvo FA, Domper M, Matute R, et al. 18 F-FDG positron emission tomography staging and restaging in rectal cancer treated with preoperative chemoradiation. Int J Radiat Oncol Biol Phys 2004;58:528-535.
294. Findlay M, Young H, Cunningham D, et al. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol 1996;14:700-708.
295. Vitola JV, Delbeke D, Meranze SG, et al. Positron emission tomography with F-18-fluorodeoxyglucose to evaluate the results of hepatic chemoembolization. Cancer (Phila) 1996;78: 2216-2222.
296. Torizuka T, Tamaki N, Inokuma T, et al. Value of fluorine-18-FDG PET to monitor hepatocellular carcinoma after interventional therapy. J Nucl Med 1994;35(12):1965-1969.
297. Langenhoff BS, Oyen WJ, Jager GJ, et al. Efficacy of fluorine-18- deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: a prospective study. J Clin Oncol 2002;20:4453-4458.
298. Wong CY, Salem R, Raman S, et al. Evaluating 90 Y-glass microsphere treatment response of unresectable liver metastases by FDG-PET: a comparison with CT and MRI. Eur J Nucl Med Mol Imaging 2002;29:815-820.
299. Schirrmeister H, Gulhman A, Elsner K, et al. Sensitivity in detecting osseous lesions depends on anatomic location: planar scintigraphy versus 18 F PET. J Nucl Med 1999;40:1623-1629.
300. Higashi K, Clavo AC, Wahl RL. In vitro assessment of 2-fluoro-2-deoxy-d- glucose, l-methionine, and thymidine as agents to monitor early response of a human adenocarcinoma cell line to radiotherapy. J Nucl Med 1993;34:773-780.
301. Dittman H, Dohman BM, Paulsen F, et al. [ 18 F] FLT PET for diagnosis and staging of thoracic tumors. Eur J Nucl Med Mol Imaging 2003;30:1407-1412.
302. Boring C, Squires T, Tong T, et al. Cancer statistics. CA Cancer J Clin 1994;44:7-26.
303. Moog F, Bangerter M, Diederichs CG, et al. Lymphoma role of whole-body 2-deoxy-2-[F-18] fluoro-D-glucose (FDG) PET in nodal staging. Radiology 1997;203:795-800.
304. Moog F, Bangerter M, Diederichs CG, et al. Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology 1998;206:475-481.
305. Jerusalem GH, Beguin YP. Positron emission tomography in non-Hodgkin's lymphoma (NHL): relationship between tracer uptake and pathological findings, including preliminary experience in the staging of low-grade NHL. Clin Lymphoma 2002; 3:56-61.
306. Friedberg JW, Chengazi V. PET scans in the staging of lymphoma: current status. Oncologist 2003;8:438-447.
307. Hoffmann M, Kletter K, Diemling M, et al. Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-d-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type. Ann Oncol 1999;10:1185-1189.
308. Hoffmann M, Chott A, Puspok A, et al. 18 F-Fluorodeoxyglucose positron emission tomography ( 18 F-FDG-PET) does not visualize follicular lymphoma of the duodenum. Ann Hematol 2004;83:276-281.
309. Moog F, Bangerter M, Kotzerke J, et al. 18 F-Fluorodeoxy-glucose positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol 1998;16:603-609.
310. Carr R, Barrington SF, Madan B, et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 1998;91:3340-3346.
311. Okada J, Oonish H, Yoshikawa K, et al. FDG-PET for predicting the prognosis of malignant lymphoma. Ann Nucl Med 1994;8: 187-191.
312. Delbeke D, Martin WH, Morgan DS, et al. 2-Deoxy-2-[F-18] fluoro-d-glucose imaging with positron emission tomography for initial staging of Hodgkin's disease and lymphoma. Mol Imaging Biol 2002;4:104-114.
313. Hong SP, Hahn JS, Lee JD, Bae SW, Youn MJ. 18 F-Fluorodeoxyglucose- positron emission tomography in the staging of malignant lymphoma compared with CT and 67 Ga scan. Yonsei Med J 2003;44(5):779-786.
314. Sasaki M, Kuwabara Y, Koga H, et al. Clinical impact of whole body FDG-PET on staging and therapeutic decision making for malignant lymphoma. Ann Nucl Med 2002;16(5): 337-345.
315. Stumpe KDM, Urbinelli M, Steinert HC, et al. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med 1998;25:721-729.
316. Paul R. Comparison of fluorine-18-2-fluorodeoxyglucose and gallium-67 citrate imaging for detection of lymphoma. J Nucl Med 1987;28:288-292.
317. Okada J, Yoshikawa K, Imazeki K, et al. The use of FDG-PET in the detection and management of malignant lymphoma. Correlation of uptake with prognosis. J Nucl Med 1991;32:686-691.
318. Shen YY, Kao A, Yen RF. Comparison of 18 F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma. Oncol Rep 2002;9:321-325.
319. Wirth A, Seymour JF, Hicks RJ, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. Am J Med 2002;112:262-268.
320. Rini JN, Manalili EY, Hoffman MA, et al. F-18 FDG versus Ga-67 for detecting splenic involvement in Hodgkin's disease. Clin Nucl Med 2002;27:572-527.
321. Buckmann I, Reinhardt M, Elsner K, et al. 2-(Fluorine-18) fluoro-2-deoxy-d-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Cancer (Phila) 2001;91(5):889-899.
322. Schoder H, Meta J, Yap C, et al. Effect of whole-body (18)F-FDGPET imaging on clinical staging and management of patients with malignant lymphoma. J Nucl Med 2001;42(8):1139-1143.
323. Naumann R, Beuthien-Baumann B, Reiss A, et al. Substantial impact of FDG-PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma. Br J Cancer 2004; 90(3):620-625.
324. Cremerius U, Fabry U, Neuerburg J, et al. Positron emission tomography with 18 F-FDG to detect residual disease after therapy for malignant lymphoma. Nucl Med Commun 1998; 19:1055-1063.
325. Zinzani PL, Magagnoli M, Chierichetti F, et al. The role of positron emission tomography (PET) in the management of lymphoma patients. Ann Oncol 1999;10:1181-1184.
326. Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-body positron emission tomography using 18 F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999;94: 429-433.
327. Mikhaeel NG, Timothy AR, Odoherty MJ, Hain S, Maisey MN. 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma, comparison with CT. Leuk Lymphoma 2000;39:543-553.
328. Spaepen K, Stroobants S, Dupont P, et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxy-glucose [18F]FDG after first-line chemotherapy in nonHodgkin's lymphoma: is (18F) FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 2001;19(2): 414-419.
329. Weihrauch MR, Re D, Scheidhauer K, et al. Thoracic positron emission tomography using 18 F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 2001;98(10):2930-2934.
330. Spaepen K, Stroobants D, Dupont P, et al. Can positron emission tomography using 18 F-fluorodeoxyglucose (18)F-FDG PET) after first line treatment distinguish Hodgkin's disease patients who need additional therapy from others where additional therapy would mean avoidable toxicity? Br J Haematol 2001;115(2):272-278.
331. Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 2002;43(8):1018-1027.
332. Armitage JO, Wisenburger DD, Hutchins M, et al. Chemotherapy for diffuse large cell hymphoma: rapidly responding patients have more durable remissions. J Clin Oncol 1986;4:160-164.
333. Romer W, Schwaiger M. Positron emission tomography in diagnosis and therapy monitoring of patients with lymphoma. Clin Positron Imaging 1998;1:101-110.
334. Mikhaeel NG, Timothy AR, Odoherty MJ, Hain S, Maisey MN. 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma: comparison with CT. Leuk Lymphoma 2000;39:543-553.
335. Zijlstra JM, Hoekstra OS, Raijmakers PG, et al. 18 FDG positron emission tomography versus 67 Ga scintigraphy as prognosis test during chemotherapy for non-Hodgkin's lymphoma. Br J Haematol 2003;123(3):454-462.
336. Spaepen K, Stroobants S, Dupont P, et al. Early restaging positron emission tomography with (18)-F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 2003;13:1356-1363.
337. Torizuka T, Nakamura F, Kanno T, et al. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2004; 31(1):22-28.
338. Carr R, Barrington SF, Madan B, et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 1998;91(9):3340-3346.
339. Becherer A, Mitterbauer M, Jaeger U, et al. Positron emission tomography with [ 18 F]2-fluoro-d-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation. Leukemia 2002;16(2): 260-267.
340. Cremerius U, Fabry U, Wildberger JE, et al. Pre-transplant positron emission tomography (PET) using fluorine-18-fluorodeoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant 2002;30(2):103-111.
341. Schot B, van Imhoff G, Pruim J, Sluiter W, Vaalburg W, Vellenga E. Predictive value of early 18 F-fluorodeoxyglucose positron emission tomography in chemosensitive relapsed lymphoma. Br J Haematol 2003;123(2):282-287.
342. Filmont JE, Czermin J, Yap C, Silverman DH, Quon A, Phelps ME, et al. Value of F 18-fluorodeoxyglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior to and after autologous stem-cell transplantation. Chest 2003;124(2):608-613.
343. Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Maertens J, Bormans G, et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood 2003;102(1):53-59.
344. Hoskin P. FDG-PET in management of lymphoma: a clinical perspective. Eur J Nucl Med 2002;29(4):449-451.
345. Front D, Bar-Shalom R, Mor M, Haim N, Epelbaum R, Frenkel A, et al. Aggressive non-Hodgkin lymphoma: early prediction of outcome with 67Ga scintigraphy. Radiology 2000;214:253-257.
346. Jerusalem G, Beguin Y, Fassotte MF, et al. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol 2003;14:123-130.
347. Bangerter M, Moog F, Griesshammer M, et al. Role of whole body FDG-PET imaging in predicting relapse of malignant lymphoma in patients with residual masses after treatment. Radiography 1999;5:155-163.
348. Cremerius U, Fabry U, Kroll U, Zimny M, Neuerburg J, Osieka R, et al. Clinical value of FDG-PET for therapy monitoring of malignant lymphoma: results of a retrospective study in 72 patients. Nuklearmedizin 1999;38(1):24-30.
349. Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, et al. Whole body emission tomography using F-18-fluorodeoxyglucose for post treatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has a higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999;94(2):429-433.
350. Guay C, Lepine M, Verreault J, Benard F. Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation. J Nucl Med 2003;44(8):1225-1231.
351. Freudenberg LS, Antoch G, Schutt P, Beyer T, Jentzen W, Muller SP, et al. FDG-PET/CT in restaging patients with lymphoma. Eur J Nucl Med Mol Imag 2004:31(3):325-329.
352. Ora Israel, Zohar Keidar, and Rachel Bar-Shalom: Seminars in Nuclear Medicine, Vol XXXIV, No 3 (July), 2004:166-179.
353. Cancer Facts & Figures 2004, in American Cancer Society, Survellance Research, Atlanta, GA: American Cancer Society, 2004.
354. Wahl RL, Hutchins GD, Buchsbaum DJ, et al. 18F-2-deoxy-2-fluoro-D-glucose uptake into human tumor xenografts. Feasibility studies for cancer imaging with positron emission tomography. Cancer 1991;67:1544-1550.
355. Kern KA. [14C] deoxyglucose uptake and imaging in malignant melanoma. J Surg Res 1991;50:643-647.
356. Wagner JD, Schauwecker DS, Davidson D, et al. FDG-PET sensitivity for melanoma lymph node metastases is dependent on tumor volume. J Surg Oncol 2001;77:237-242.
357. Rinne D, Baum RP, Hor G, et al. Primary staging and followup of high risk melanoma patients with whole-body 18Ffluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. Cancer 1998;82:1664-1671.
358. Macfarlane DJ, Sondak V, Johnson T, et al. Prospective evaluation of 2-[18F]-2-deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma. J Clin Oncol 1998;16:1770-1776.
359. Wagner JD, Schauwecker D, Davidson D, et al. Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel nodebiopsy. J Clin Oncol 1999;17:1508-1515.
360. Acland KM, Healy C, Calonje E, et al. Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma. J Clin Oncol 2001;19:2674-2678.
361. Fink AM, Holle-Robatsch S, Herzog N, et al. Positron emission tomography is not useful in detecting metastasis in the sentinel lymph node in patients with primary malignant melanoma stage I and II. Melanoma Res 2004;14:141-145.
362. Acland KM, O'Doherty MJ, Russel-Jones R. The value of positron emission tomography scanning in the detection of subclinical metastatic melanoma. J Am Acad Dermatol 2000;42:606-611.
363. Stas M, Stroobants S, Dupont P, et al. 18-FDG PET scan in the staging of recurrent melanoma: additional value and therapeutic impact. Melanoma Res 2002;12:479-490.
364. Blessing C, Feine U, Geiger L, et al. Positron emission tomography and ultrasonography: a comparative retrospective study assessing the diagnostic validity in lymph node metastases of malignant melanoma. Arch Dermatol 195;131:1394-1398.
365. Crippa F, Leutner M, Belli F, et al. Which kinds of lymph node metastases can FDG PET detect? A clinical study in melanoma. J Nucl Med 2000;41:1491-1494.
366. Tyler DS, Onaitis M, Kherani A, et al. Positron emission tomography scanning in malignant melanoma. Cancer (Phila) 2000;89:1019-1025.
367. Wagner JD, Schauwecker D, Hutchins G, et al. Initial assessment of positron emission tomography for detection of nonpal pable regional lymphatic metastases in melanoma. J Surg Oncol 1997;64:181-189.
368. Gritters LS, Francis IR, Zasadny KR, et al. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-d-glucose in the imaging of malignant melanoma. J Nucl Med 1993;34:1420-1427.
369. Steinert HC, Huch Boni RA, Buck A, et al. Malignant melanoma: staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-d- glucose. Radiology 1995;195:705-709.
370. Rinne D, Baum RP, Hor G, et al. Primary staging and followup of high risk melanoma patients with whole-body 18 Ffluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. Cancer (Phila) 1998; 82:1664-1671.
371. Eigtved A, Andersson AP, Dahlstrom K, et al. Use of fluorine-18- fluorodeoxyglucose positron emission tomography in the detection of silent metastases from malignant melanoma. Eur J Nucl Med 2000;27:70-75.
372. Swetter SM, Carroll LA, Johnson DL, et al. Positron emission tomography is superior to computed tomography for metastatic detection in melanoma patients. Ann Surg Oncol 2002;9: 646-653.
373. Gulec SA, Faries MB, Lee CC, et al. The role of fluorine-18 deoxyglucose positron emission tomography in the management of patients with metastatic melanoma: impact on surgical decision making. Clin Nucl Med 2003;28:961-965.
374. Dietlein M, Krug B, Groth W, et al. Positron emission tomography using 18 F-fluorodeoxyglucose in advanced stages of malignant melanoma: a comparison of ultrasonographic and radiological methods of diagnosis. Nucl Med Commun 1999;20:255-261.
375. Krug B, Dietlein M, Groth W, et al. Fluoro-18-fluorodeoxyglucose positron emission tomography (FDG-PET) in malignant melanoma: diagnostic comparison with conventional imaging methods. Acta Radiol 2000;41:446-452.
376. Mercier GA, Alavi A, Fraker DL. FDG positron emission tomography in isolated limb perfusion therapy in patients with locally advanced melanoma: preliminary results. Clin Nucl Med 2001;26:832-836.
377. Hafner J, Schmid MH, Kempf W, et al. Baseline staging in cutaneous malignant melanoma. Br J Dermatol 2004;150:677-686.
378. Havenga K, Cobben DC, Oyen WJ, et al. Fluorodeoxyglucose - positron emission tomography and sentinel lymph node biopsy in staging primary cutaneous melanoma. Eur J Surg Oncol 2003;29:662-664.
379. Lindholm P, Leskinen S, Nagren K, et al. Carbon-11-methionine PET imaging of malignant melanoma. J Nucl Med 1995;36: 1806-1810.
380. Mishima Y, Imahori Y, Honda C, et al. In vivo diagnosis of human malignant melanoma with positron emission tomography using specific melanoma-seeking 18 F-DOPA analogue. J Neurooncol 1997;33:163-169.
381. Gobben DC, Jager PL, Elsinga PH, et al. 3-18 F-fluoro-3-deoxyl-thymidine: a new tracer for staging metastatic melanoma? J Nucl Med 2003;44:1927-1932.
382. Sadzot B, Sheldon J, Flesher J, et al. Tracers for imaging melanin with positron emission tomography. Synapse 1999;31:5-12.
383. Froidevaux S, Calame-Christe M, Schuhmacher J, et al. A gallium-labeled DOTA-alpha-melanocyte-stimulating hormone analog for PET imaging of melanoma metastases. J Nucl Med 2004;45:116-123.